FA
MIRM icon

Forefront Analytics’s Mirum Pharmaceuticals MIRM Stock Holding History

Forefront Analytics’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,663
Closed -$210K – 46
2025
Q4 		$210K Buy
+2,663
New +$191K 0.19% 35

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Forefront Analytics's MIRM Position: Q1 2026 in Review

Forefront Analytics sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 2,663 shares — an estimated $210K sold.

Forefront Analytics first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $210K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Forefront Analytics reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Forefront Analytics sold 2,663 Mirum Pharmaceuticals shares in Q1 2026, an estimated $210K.
  • Forefront Analytics first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Forefront Analytics's Mirum Pharmaceuticals position peaked at $210K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Forefront Analytics's 13F filing for Q1 2026, filed 13 May 2026.